Company intelligence

ZNTL

Zentalis Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$4.03+1.00% · +$0.04

Market cap286.88MEquity value

P / E-2.1Trailing ratio

Volume518.74KLatest session

Market data

ZNTL price chart

TradingView

Related signals

1 min delayed

Browse public ZNTL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ZNTLApr 10, 2026-4.91% since signal

Guggenheim Raises Zentalis Price Target, Shares Surge to New High

Zentalis Pharmaceuticals (ZNTL) shares rose 31.9% after Guggenheim upgraded the price target to $10. The stock's momentum is fueled by the selection of an optimal dose for its ovarian cancer treatment, with upcoming earnings expected to further influence its prospects.

View signal analysis

ZNTLSep 16, 2024+26.54% since signal

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

FDA lifted the partial clinical hold on Zentalis’ azenosertib studies. Zentalis to resume enrollment in all ongoing azenosertib clinical studies. Company plans to present azenosertib data at a corporate event this year. ZNTL stock rose 41.7% to $4.59 in premarket trading.

View signal analysis

Research